A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Registered clinical trial record on ClinicalTrials.gov (NCT07639021). This describes a planned, ongoing, or completed study — it is NOT peer-reviewed results. Status: not yet recruiting. Study type: interventional. Phase: Phase 2. Sponsor: Novo Nordisk A/S. Conditions: Obesity. Interventions: NNC0662-0419, Semaglutide, NNC0662-0419 Placebo, Semaglutide placebo. Summary: The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity. Primary outcome measures: Number of gastrointestinal adverse events. Eligibility: Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.